Bristol Pravachol OTC Label Studies, Redefined Population Urged By Cmte.
Executive Summary
Bristol-Myers Squibb's Pravachol (pravastatin) 10 mg is an attractive candidate for OTC status, but the company should first conduct additional label comprehension studies and better define the target population for the cholesterol agent, FDA advisory committee members suggested July 14.
You may also be interested in...
OTC Pravachol Use Among Rx Patients Needs More Study, FDA Cmte. Says
The reason individuals switch from taking prescription cholesterol-lowering agents to OTC Pravachol (pravastatin) in actual use studies should be the subject of additional research, FDA advisory committee members suggested to Bristol-Myers Squibb July 14.
Pravachol Rx Interaction Profile Is Viewed Favorably In Statins OTC Review
The drug interaction profile of Bristol-Myers Squibb's Pravachol may make the cholesterol-lowering agent a more attractive OTC switch candidate than Merck's Mevacor, members of the statin OTC switch advisory committee suggested.
Bristol OTC Pravachol Study Enrollment Does Not Match Indication - FDA
Bristol-Myers Squibb may need to better demonstrate consumers' ability to make self-selection choices based on appropriate cholesterol levels in order to convince FDA that an OTC version of Pravachol is approvable.